Skip to search formSkip to main contentSkip to account menu

panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionHistone DeacetylaseNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (4)

Antineoplastic AgentsHistone deacetylase inhibitorHydroxamic AcidsIndoles

Narrower (1)

LBH589

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
Hodgkin lymphoma (HL) relapsing after an autologous hematopoietic cell transplant (HCT) poses a therapeutic challenge. In this… 
2013
2013
Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma
Background Multiple myeloma (MM) remains an incurable disease, with a high unmet need for patients (pts) in the relapsed and… 
2012
2012
PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma
Abstract 1852 Background: There are limited treatment options for patients (pts) with multiple myeloma (MM) whose disease is… 
2012
2012
Phase I/II Study of Panobinostat and Carfilzomib in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Interim Phase I Safety Analysis
Abstract 4048 Background: Proteasome inhibitors (PI) such as bortezomib and carfilzomib (CFZ) have improved the treatment of MM… 
2012
2012
Biocatalytic Synthesis and Structure Elucidation of Cyclized Metabolites of the Deacetylase Inhibitor Panobinostat (LBH589)
Panobinostat (LBH589) is a novel pan-deacetylase inhibitor that is currently being evaluated in phase III clinical trials for… 
2012
2012
A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)
Introduction: Phase 2 single agent trials with lenalidomide and panobinostat in patients with relapsed or refractory HL have… 
2011
2011
Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,
Abstract 3976 Background: The outcomes of patients with multiple myeloma (MM) have significantly improved in recent years mainly… 
2011
2011
Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
Abstract 814 Background: Patients with refractory multiple myeloma (MM) have limited treatment options and an extremely poor… 
2010
2010
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
1115 Background: In vivo experiments have demonstrated synergy when the histone deacetylase (HDAC) inhibitors are combined with… 
2009
2009
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma
Panobinostat is a novel cinnamic hydroxamic acid pan-deacetylase inhibitor able to induce hyperacetylation of lysine residues on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)